蒲公英 - 制药技术的传播者 GMP理论的实践者

搜索
查看: 2046|回复: 3
收起左侧

[行业动态] 诺华旗下的SANDOZ准备出售其美国仿制药业务

[复制链接]
药士
发表于 2018-3-2 09:06:42 | 显示全部楼层 |阅读模式

欢迎您注册蒲公英

您需要 登录 才可以下载或查看,没有帐号?立即注册

x
诺华旗下的SANDOZ准备出售其美国仿制药业务

Fake news? Novartis confirms it has no plans to sell SandozBy Dan Stanton
26-Feb-2018 - Last updated on 26-Feb-2018 at 13:44 GMT





GettyImages/milindriNovartis is considering divesting non-core and negative margin products but confirms it has no plans to place Sandoz “on the auction block.”

A Reuters report​ based on “people familiar with the matter” ​said recently that Novartis is preparing to auction off its US generic oral solid dose business.
But as is often the case, the rumoured sale was picked up by other media outlets and soon the story had resurfaced under the headline: “Novartis Could Put Sandoz on the Auction Block Within a Few Weeks.”​​
This is far from the truth, a spokesperson from Sandoz told in-Pharmatechnologist.
Sandoz is a $10bn global subsidiary of Swiss Pharma giant Novartis, and is itself made up of a number of business units.
Therefore the idea that Novartis is looking to auction off Sandoz (and for as little as $1.6bn as some media reports stated) is false, we were told.
However, the US generics business – which falls under the Sandoz brand – could be sold off, it was confirmed, as part of a strategy previously announced by Novartis.
While the firm was unable to comment directly on any sales speculation, it told us it is following a strategy to reshape its US business towards a more specialised and differentiated portfolio.
“As part of this ongoing process we are also looking at potentially divesting or discontinuing certain non-core or negative margin products.”​
The statement is in line with what management said in its end-of-year financial call last month (transcript here​):
“Our energy is focused primarily of looking at the US oral solids business where it is a discrete business, it's a unique situation. There are significant pricing declines. At least in the medium term, we don't see a shift to that situation. So we are assessing how best to optimise that given that dynamic.”​



Copyright - Unless otherwise stated all contents of this web site are © 2018 - William Reed Business Media Ltd - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions



回复

使用道具 举报

药士
 楼主| 发表于 2018-3-2 09:13:23 | 显示全部楼层
城里的人想出来,城外的人想进去
回复

使用道具 举报

药生
发表于 2018-3-2 09:20:17 | 显示全部楼层
Fake news

点评

可以看看文章再回答!谢谢!  发表于 2018-3-2 09:22
回复

使用道具 举报

您需要登录后才可以回帖 登录 | 立即注册

本版积分规则

×发帖声明
1、本站为技术交流论坛,发帖的内容具有互动属性。您在本站发布的内容:
①在无人回复的情况下,可以通过自助删帖功能随时删除(自助删帖功能关闭期间,可以联系管理员微信:8542508 处理。)
②在有人回复和讨论的情况下,主题帖和回复内容已构成一个不可分割的整体,您将不能直接删除该帖。
2、禁止发布任何涉政、涉黄赌毒及其他违反国家相关法律、法规、及本站版规的内容,详情请参阅《蒲公英论坛总版规》。
3、您在本站发表、转载的任何作品仅代表您个人观点,不代表本站观点。不要盗用有版权要求的作品,转贴请注明来源,否则文责自负。
4、请认真阅读上述条款,您发帖即代表接受上述条款。

QQ|手机版|蒲公英|ouryao|蒲公英 ( 京ICP备14042168号-1 )  增值电信业务经营许可证编号:京B2-20243455  互联网药品信息服务资格证书编号:(京)-非经营性-2024-0033

GMT+8, 2025-9-10 16:32

Powered by Discuz! X3.4

Copyright © 2001-2020, Tencent Cloud.

声明:蒲公英网站所涉及的原创文章、文字内容、视频图片及首发资料,版权归作者及蒲公英网站所有,转载要在显著位置标明来源“蒲公英”;禁止任何形式的商业用途。违反上述声明的,本站及作者将追究法律责任。
快速回复 返回顶部 返回列表